A number of equities analysts have recently weighed in on the stock. Piper Sandler assumed coverage on shares of Summit Therapeutics in a research report on Monday, August 18th. They issued a "neutral" rating and a $21.00 price objective for the company. Leerink Partnrs upgraded Summit Therapeutics to a "strong sell" rating in a report on Wednesday, June 11th. Summit Redstone set a $21.00 price objective on Summit Therapeutics in a research report on Tuesday, August 19th. JMP Securities reiterated a "market outperform" rating and set a $40.00 target price on shares of Summit Therapeutics in a research report on Wednesday, September 3rd. Finally, Evercore ISI raised their price target on Summit Therapeutics from $30.00 to $34.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 12th.